Analyst Sumant Kulkarni works at CANACCORD and is focused on the Healthcare sector with 209 price targets and ratings documented since 2017 spanning on 14 stocks. Analyst's average stock valuation to be materialised ratio is 46.73% with an average time for price targets to be met of 206.77 days.
Most recent stock forecast was given on ACAD, ACADIA Pharmaceuticals Inc at 22-Jun-2022.
Sumant Kulkarni best performing recommendations are on CRTX (CORTEXYME, INC).
The best stock recommendation documented was for CRTX (CORTEXYME, INC) at 6/3/2019. The price target of $42 was fulfilled within 15 days with a profit of $17.87 (74.06%) receiving and performance score of 49.37.
Average potential price target upside
